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In his commentary in Environmental Health 
Perspectives, Calabrese (2009) offered a num­
ber of responses to my critique of hormesis 
methodology (Mushak 2009). Here I will 
provide a counterpoint to that effort. 
• Calabrese (2009) falsely asserted that I erred 
in calculations associated with entry and 
evaluatory criteria for hormesis frequency, 
specifically by choosing the wrong denomi­
nator for examining the proportion of entry 
candidates eventually found to be hormetic 
using the most conventional form of statis­
tical significance. The choice of a denomi­
nator for these calculations depends on 
the question asked. My key question was, 
What proportions of 668 dose–response 
entry candidates from 20,285 original arti­
cles, using the three criteria identified by 
Calabrese and Baldwin (2001), partition 
into each of three hormesis categories? A 
total of 245 of the 668 candidate dose–
responses (37%) had hormetic character, 
but only 74 of those (30%) were derived 
using the typical statistical significance test, 
yielding 11% overall. 
• Calabrese (2009) mis  charac  terized my 
statements about the reliability of the two 
unvali  dated selection criteria (Mushak 
2009). My comments addressed applying 
criteria to screening large databases of pub­
lications for a putative new phenomenon. 
I was not concerned about routine uses of 
statistical forms for empirical data (e.g., 
analyses using 95% confidence intervals on 
independent means). 
• Calabrese (2009) misunderstood my con­
cerns about the two tallies of dosing points 
(1,089 and 1,791 points) from two of his 
previous studies (Calabrese and Baldwin 
2001, 2003b). The still unanswered ques­
tion is how the 871 (80% of 1,089) 
control­equivalent and threshold response–
compatible dosing points reported by 
Calabrese and Baldwin (2001) are mathe­
matically incorporated into a high pre­
ponderance of hormetic dosing points (to 
a 2.5:1 ratio) they reported later (Calabrese 
and Baldwin 2003b). I was not concerned 
about simple counts.
• Calabrese mis  interpreted my concern about 
clustered distributions in entry candidates 
in the 20,285 articles. I was not referring 
to publications in which the same informa­
tion is recapitulated in multiple articles, but 
whether serial publications that described a 
given experimental approach but tested 
different substances were included in the 
articles database. The clustering pattern, 
although important, remains unexplained. 
• Calabrese stated that the use of entry and 
evaluation criteria had been validated for 
both sensitivity and specificity. The ques­
tion here is whether entry and evaluation 
criteria that established the original sets of 
hormetic, false­positive, and false­negative 
values were validly derived. 
• Calabrese (2009) mis  under  stood and mis­
applied my rationale for including single 
sub­NOAEL (no observed adverse effect 
level) dosing points in the original data­
base. He stated that virtually all of the dos­
ing points within the selected 664 dose 
responses had been identified previously 
(Calabrese and Baldwin 2003b). However, 
in my commentary (Mushak 2009), I 
clearly conveyed that this step itself had 
an inherent positive bias and that it is not 
surprising that hormetic responses out­
numbered negative ones. Calabrese was 
incorrect that including single sub­NOAEL 
points from the 20,285 articles adds nega­
tive bias; rather, such inclusion offsets and 
corrects an inherent positive bias. 
• Calabrese challenged my discussion of the 
National Cancer Institute (NCI) yeast data 
set, arguing that the Crump analysis noted 
in my commentary (Crump 2007) was not 
peer­reviewed [of course, neither was the 
rebuttal letter by Calabrese et al. (2007) 
peer­reviewed]. Calabrese missed the point: 
Which of two plausible alternatives better 
addresses the truth of hormesis being pres­
ent in the NCI data set? Calabrese (2009) 
noted that Crump’s approach introduced 
8­fold more variability into the control 
group statistics, accounting for lack of hor­
metic evidence. Thereby, he conceded that 
alleged hormesis in the NCI yeast data lies 
within the range of determinable control 
(i.e., non  hormetic) responses. 
• Calabrese (2009) challenged my critique of 
an earlier article on the National Toxicology 
Program dose­ranging program (Calabrese 
and Baldwin 2003a). He asserted that all 
levels of evidence should combine to support 
the cumulative 31% hormesis frequency. I 
disagree that poor evidence is just as good 
as strong evidence; only their “moderate to 
high” and “high” evidence should have been 
used in their analysis, yeilding a combined 
2.3% frequency and not the claimed 31%.
The data of Calabrese and Baldwin (2003a) 
provided little meaningful support for 31% 
hormetic frequency. 
• Calabrese (2009) objected to my discussing 
the language issues for hormesis; he argued 
that (hormesis) revisions are part of the 
nature of science and new phenomenology, 
and ignored my point that current hormesis 
definitions are either those of interpretive 
convenience or represent divergence rather 
than convergence (the usual path). One defi­
nition in my commentary (Mushak 2009) 
explained hormesis as an over  compensation 
for homeo  static preservation; the only 
discernible basis is as an explanation for 
U(J)­shaped or inverted U(J)­shaped curves. 
Another definition explained hormesis as 
three divergent phenomena. 
• Calabrese (2009) took strong exception 
to my view that public agencies have been 
slow to address and accommodate horme­
sis within policy formulations. Regulatory 
agencies dealing with xeno  biotics and 
human or ecologic health—the key issue—
have not adopted hormesis.
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Hormesis: Calabrese Responds
doi:10.1289/ehp.0901681R
In his letter, Mushak revisits his criticism 
(Mushak 2009) of previously reported 
hormesis frequency estimates (Calabrese and 
Baldwin 2001, 2003; Calabrese et al. 2006, 
2008). In my commentary (Calabrese 2009), 
I addressed and/or rebutted in consider­
able detail his arguments (Mushak 2009), 
and no new data require me to revise that 
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by Mushak’s letter, two of which relate to 
the frequency of hormesis, and the third 
considers the acceptance of hormesis by the 
scientific and regulatory communities. 
First, a central point of Mushak’s com­
mentary (Mushak 2009) and his letter is his 
assertion that the reported hormesis frequency 
of 37% (Calabrese and Baldwin 2001) is 
incorrect and should be 11%. Unfortunately, 
Mushak used the wrong denominator in his 
commentary, and he perpetuates this error in 
his letter. Briefly, we (Calabrese and Baldwin 
2001) estimated the frequency of horme­
sis using a priori entry and evalua  tive crite­
ria; some 668 dose responses satisfied the 
entry criteria. There were three independent 
evalua  tive criteria (i.e., hypothesis testing, 
non  overlapping 95% confidence intervals, 
and alternative quantitative criteria). Of the 
668 dose responses, 213 (31.8%) involved 
hypothesis testing. Of this total, 74 (74/213; 
34.7%) satisfied the evaluative criteria for 
hormesis, a percentage similar to the other 
two evaluative approaches. When totaled, 
the three approaches yielded the 37% esti­
mate. Mushak’s error is that he used the 
74 dose responses that satisfied the evalua­
tive criteria for hypothesis testing not only 
against the 213 dose responses that had 
hypothesis testing (which would have been 
a correct approach) but against all 668 dose 
responses, even though the remaining 
455 dose responses that satisfied the entry cri­
teria lacked hypothesis testing. None of these 
455 dose responses could have been evalu­
ated by the statistical criteria. Nonetheless, 
Mushak combined all the dose responses 
that satisfied the entry criteria and derived 
a hormesis frequency based on only dose 
responses with statistical significance. In so 
doing, he mistakingly reduced the 37% fre­
quency to 11%. His method is the equivalent 
of using a raw score for the math component 
of the Graduate Record Examination (GRE) 
as the only source of correct answers, and 
then using all the questions on the math, 
verbal, and analytic components of the exam 
as the denominator, even though the student 
did not take these other components of the 
test. Such a calculation would give a useless 
GRE score. His method of hormesis calcula­
tion is clearly why he obtained the incorrect 
lower frequency. 
Second, in his leter Mushak continues 
to cite a letter by Crump (2007) for which 
there is no support in the literature; also, 
Crump’s letter is based on an assumption 
about methods that was refuted by the 
National Cancer Institute investigators who 
actually did the original work (Calabrese 
et al. 2007). Mushak apparently does not 
grasp that Crump’s exercise inappropriately 
introduced 8­fold more variability into the 
data analysis. In his leter, Mushak incor­
rectly and inexplicably claimed that Crump’s 
analy  sis resulted in my conceding that the 
hormetic responses that we reported were 
not different from control responses.
Third, Mushak’s inflexibility concern­
ing hormesis is reflected in his comments 
that minimize the impact of hormesis and 
its growing applications. Despite the signifi­
cant biomedical impact of hormesis, Mushak 
fails to acknowledge the reality that hormetic 
effects are the basis for how most anxiolytic 
(Calabrese 2008a), anti  seizure (Calabrese 
2008b), memory (Calabrese 2008c; Zoladz 
and Diamond 2009), Alzeheimer disease 
(Calabrese 2008c; Congdon et al. 2009), and 
numerous other classes of drugs work (Kastin 
and Pan 2008; Mattson 2008; Sonneborn 
2008; Thong and Maibach 2008), with all 
such drugs having to pass the regulatory over­
sight of the Food and Drug Administration 
for efficacy and safety. On the environ­
mental side, Mushak—in both his letter and 
his commentary (Mushak 2009)—did not 
acknowledge that the largest­ever rodent can­
cer bioassay (24,000 mice) that was designed 
to determine the nature of the dose response 
in the low­dose zone for carcinogens revealed 
hormetic responses for acetyl aminofluorene­ 
induced bladder cancer and that this was 
affirmed by the 14­member Society of 
Toxicology expert panel convened to assess 
these findings (Society of Toxicology ED01 
Task Force 1981). In both his letter and his 
commentary (Mushak 2009), he also failed 
to acknowledge that hormesis has had a 
meteoric rise in recog  nition and journal cita­
tions within the scientific community, with 
15 citations per year in the 1980s to > 2,400 
in 2009 alone.
On these grounds and those presented 
in my commentary (Calabrese 2009), I con­
clude that Mushak’s arguments are without 
merit. 
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Lead in Drinking Water as a 
Public Health Challenge
doi:10.1289/ehp.1001979
In drinking water supplies the intake of the 
toxic heavy metal lead is commonly due to 
metal corrosion in the peripheral water distri­
bution system, especially the user’s plumbing 
or lead service lines. Recently, the prob­
lem again received attention in the United 
States when testing data of drinking water 
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at schools was published (Renner 2009). 
In Europe several countries are known to 
have significant numbers of buildings with 
elevated lead tap water concentrations, for 
example, the United Kingdom (Watt et al. 
1996), Austria (Haider et al. 2002) and 
Germany (Becker et al. 2001).
Lead exposure from drinking water has 
been a topic of public health prevention pro‑
grams in several parts of Germany before, for 
example, Hamburg (Fertmann et al. 2004) 
and Frankfort (Hentschel et al. 1999). In 
2005 in the northern German state of Lower 
Saxony, a prevention program was initi‑
ated comprising three different approaches 
at the same time to achieve a widespread 
effect. To assess the present state of drink‑
ing water contamination with lead, a free 
examination of lead in tap water (after noc‑
turnal stagnation) was offered in coopera‑
tion with local public health departments 
for private households that included young 
women and families with children (Zietz 
et al. 2007, 2009). Along with the collection 
of data, the program aimed to focus public 
attention on this public health problem. In 
another part of this program, data from local 
public health departments on existing lead 
measurements, especially in public build‑
ings, were collected and analyzed (Zietz et al. 
2007, 2009). Finally, a working group on 
lead replacement, consisting of representa‑
tives of all relevant parties (e.g., tenant and 
landlord associations, crafts people, building 
and health administrations) was initiated. In 
the screening part of the project, a total of 
2,901 tap water samples from households 
were collected during 2005–2007. Of these, 
7.5% had lead concentrations > 10 µg/L 
(recommended limit of the World Health 
Organization) and 3.3% had concentrations 
above the present limit of the German drink‑
ing water ordinance (25 µg/L) (Zietz et al. 
2009). We found remarkable regional differ‑
ences in the frequency of tap water contami‑
nation. An additional inclusion criterion in 
this study was that buildings must have been 
constructed before 1974 (after which no 
new lead pipes were installed); therefore, the 
results cannot be compared directly to other 
studies. From the data, we roughly estimated 
that about 4.7% of all households in Lower 
Saxony have lead concentrations > 10 µg/L 
(Zietz et al. 2009). In an earlier study in 
southern Lower Saxony (Zietz et al. 2001a), 
households with mothers of newborn babies 
from the area around the university city of 
Göttingen were investigated. Of the 1,434 
stagnation samples, 3.1% had lead concen‑
trations > 10 µg/L. 
A moderately higher percentage of house‑
holds with elevated composite water samples 
was found in the geographic area of the city 
of Berlin using two composite water sampling 
methods (5.6% and 7.0%, respectively. In 
total, 2,109 households were tested with 
both methods in the federal state of Berlin 
(Zietz et al. 2001b). In a representative study 
of samples collected in all parts of Germany 
during 1997–1999 (Becker et al. 2001), the 
90th percentile of lead concentrations in 
4,761 stagnation samples was 7.6 µg/L. 
Projects in association with epidemiologi  c 
investigations also provide an opportu‑
nity to design prevention programs in this 
field. Generally, we favor the precaution‑
ary measure of preventing exposure to lead 
by replacing pipes completely. The addition 
of anti  corrosive substances to the public 
water supply can be effective in lowering 
lead concentrations. In contrast, changing 
water chemis  try (e.g., a new water disinfect‑
ant method, as in Washington, DC, USA) 
can have a substantial effect in elevating lead 
(Renner 2009). Flushing the water pipes and 
using only cold water are short‑term methods   
of decreasing exposure to lead from tap 
water. Using bench‑top water filters can also 
decrease lead concentrations, but problems 
such as leaching of different substances into 
the water or microbial contamination may 
arise under certain conditions. Thus, lead 
plumbing material in buildings still poses 
a challenge for public health in the United 
States and in Europe.
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Editor’s note: A second feature by Rebecca 
Renner in the February 2010 issue of EHP 
[Environ Health Perspect 118:A68–A72] fur-
ther explored tap water as a source of potential 
lead exposure. A third feature in the May 2010 
issue will address the public health implications 
of partial replacement of lead service lines. 
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